{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:58:52Z","timestamp":1787068732142,"version":"build-2736575974"},"reference-count":264,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016728","name":"Kyoto Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016728","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016289","name":"Taiju Life Social Welfare Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25KJ2197"],"award-info":[{"award-number":["25KJ2197"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K28411"],"award-info":[{"award-number":["23K28411"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K10644"],"award-info":[{"award-number":["25K10644"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.pharmthera.2026.109084","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:43:23Z","timestamp":1784533403000},"page":"109084","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies"],"prefix":"10.1016","volume":"286","author":[{"given":"Daijiro","family":"Yanagisawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ohgita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Tooyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00401-023-02672-z","article-title":"Head-to-head comparison of [18F]-Flortaucipir, [18F]-MK-6240 and [18F]-PI-2620 postmortem binding across the spectrum of neurodegenerative diseases","volume":"147","author":"Aguero","year":"2024","journal-title":"Acta Neuropathologica"},{"issue":"39","key":"10.1016\/j.pharmthera.2026.109084_bb0010","doi-asserted-by":"crossref","first-page":"13720","DOI":"10.1021\/jacs.7b05012","article-title":"Molecular mechanism for the (\u2212)-epigallocatechin Gallate-induced toxic to nontoxic remodeling of A\u03b2 oligomers","volume":"139","author":"Ahmed","year":"2017","journal-title":"Journal of the American Chemical Society"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41582-022-00645-6","article-title":"Early-stage Alzheimer disease: Getting trial-ready","volume":"18","author":"Aisen","year":"2022","journal-title":"Nature Reviews Neurology"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109084_bb0020","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1074\/jbc.RA119.012517","article-title":"Phosphorylation of the overlooked tyrosine 310 regulates the structure, aggregation, and microtubule- and lipid-binding properties of tau","volume":"295","author":"Ait-Bouziad","year":"2020","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/joim.13332","article-title":"Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer\u2019s disease","volume":"290","author":"Alawode","year":"2021","journal-title":"Journal of Internal Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb0030","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1016\/S1470-2045(24)00145-1","article-title":"Translating the theranostic concept to neuro-oncology: Disrupting barriers","volume":"25","author":"Albert","year":"2024","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1395563","article-title":"Enhancing Alzheimer\u2019s disease diagnosis and staging: A multistage CNN framework using MRI","volume":"15","author":"Ali","year":"2024","journal-title":"Frontiers in Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11064-023-04036-1","article-title":"Stabilization and reduced cytotoxicity of amyloid Beta aggregates in the presence of catechol neurotransmitters","volume":"49","author":"Allnutt","year":"2024","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fncel.2018.00338","article-title":"Hyperphosphorylation of tau associates with changes in its function beyond microtubule stability","volume":"12","author":"Alonso","year":"2018","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0318620","article-title":"Ensemble deep learning for Alzheimer\u2019s disease diagnosis using MRI: Integrating features from VGG16, MobileNet, and InceptionResNetV2 models","volume":"20","author":"Alruily","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103836","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease","volume":"76","author":"Ashton","year":"2022","journal-title":"eBioMedicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb0060","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: A new biomarker for incipient Alzheimer\u2019s disease pathology","volume":"141","author":"Ashton","year":"2021","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0065","article-title":"Neuroprotection by curcumin: A review on brain delivery strategies","volume":"585","author":"Askarizadeh","year":"2020","journal-title":"International Journal of Pharmcuetics."},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0070","doi-asserted-by":"crossref","first-page":"25741","DOI":"10.1038\/s41598-024-75204-8","article-title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer\u2019s disease: A systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","volume":"14","author":"Avgerinos","year":"2024","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0075","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/MS9.0000000000004609","article-title":"FDA approval of the Lumipulse G PTau217\/\u03b2-amyloid 1-42 plasma ratio test: A new era in accessible Alzheimer\u2019s diagnosis","volume":"88","author":"Ayalew","year":"2026","journal-title":"Annals of Medicine and Surgery"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0080","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3390\/biomedicines11010149","article-title":"Hybridized deep learning approach for detecting Alzheimer\u2019s Disease","volume":"11","author":"Balaji","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2019.00121","article-title":"Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer\u2019s disease","volume":"11","author":"Barth\u00e9lemy","year":"2019","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0090","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3233\/JAD-210677","article-title":"Site-specific cerebrospinal fluid tau hyperphosphorylation in response to Alzheimer\u2019s Disease brain pathology: Not all tau Phospho-sites are Hyperphosphorylated","volume":"85","author":"Barth\u00e9lemy","year":"2022","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0095","article-title":"Tau hyperphosphorylation impairs cooperative binding to microtubules and perturbs organelle trafficking in neurons","author":"Beaudet","year":"2026","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb0100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2019.01.056","article-title":"A quarter century of APOE and Alzheimer\u2019s Disease: Progress to date and the path forward","volume":"101","author":"Belloy","year":"2019","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic a\u03b2 oligomer and Alzheimer's disease: An emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nature Neuroscience"},{"issue":"40","key":"10.1016\/j.pharmthera.2026.109084_bb0110","doi-asserted-by":"crossref","first-page":"23202","DOI":"10.1039\/D5NR02548F","article-title":"Crossing the blood\u2013brain barrier: Advances in dendrimer-based nanocarriers for central nervous system delivery","volume":"17","author":"Bharadwaj","year":"2025","journal-title":"Nanoscale"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/bies.202200086","article-title":"Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases","volume":"44","author":"Bigi","year":"2022","journal-title":"BioEssays"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb0120","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1007\/s00259-020-05156-4","article-title":"Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"48","author":"Bischof","year":"2021","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02815140","article-title":"Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?","volume":"26","author":"Blennow","year":"1995","journal-title":"Molecular and Chemical Neuropathology"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109084_bb0130","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s00259-019-04462-w","article-title":"Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease","volume":"46","author":"Boche","year":"2019","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0135","article-title":"Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer\u2019s disease","volume":"13","author":"Borkowski","year":"2021","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0140","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuroimage.2018.08.044","article-title":"Implementing the centiloid transformation for 11C-PiB and \u03b2-amyloid 18F-PET tracers using CapAIBL","volume":"183","author":"Bourgeat","year":"2018","journal-title":"NeuroImage"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13195-022-01117-1","article-title":"The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer\u2019s disease: A literature review","volume":"14","author":"Brand","year":"2022","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"338","key":"10.1016\/j.pharmthera.2026.109084_bb0150","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and a\u03b2 imaging, CSF measures, and cognition in Alzheimer\u2019s disease","volume":"8","author":"Brier","year":"2016","journal-title":"Science Translational Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0155","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0160","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archgenpsychiatry.2011.155","article-title":"Cerebrospinal fluid levels of\u03b2-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia","volume":"69","author":"Buchhave","year":"2012","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0165","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2967\/jnumed.123.266463","article-title":"Evaluation of neurodegenerative disorders with amyloid-\u03b2, tau, and dopaminergic PET imaging: Interpretation pitfalls","volume":"65","author":"Burkett","year":"2024","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2024.1465871","article-title":"Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: A systematic review and network meta-analysis of randomized controlled trials","volume":"16","author":"Cai","year":"2025","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0175","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/v11111044","article-title":"Transmissibility versus pathogenicity of self-propagating protein aggregates","volume":"11","author":"Caughey","year":"2019","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0180","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12551-017-0353-8","article-title":"Recent progress on understanding the mechanisms of amyloid nucleation","volume":"10","author":"Chatani","year":"2018","journal-title":"Biophysical Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0185","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41380-024-02656-9","article-title":"PET imaging of neuroinflammation: Any credible alternatives to TSPO yet?","volume":"30","author":"Chauveau","year":"2025","journal-title":"Molecular Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0190","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4103\/1673-5374.230303","article-title":"Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease","volume":"13","author":"Chen","year":"2018","journal-title":"Neural Regeneration Research"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb0195","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamaneurol.2018.1836","article-title":"Assessing synaptic density in Alzheimer Disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurology"},{"issue":"42","key":"10.1016\/j.pharmthera.2026.109084_bb0200","doi-asserted-by":"crossref","first-page":"8188","DOI":"10.1523\/JNEUROSCI.1246-20.2020","article-title":"14,15-epoxyeicosatrienoic acid alleviates pathology in a mouse model of Alzheimer's Disease","volume":"40","author":"Chen","year":"2020","journal-title":"The Journal of Neuroscience"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0205","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1177\/0271678X20985946","article-title":"Understanding the brain uptake and permeability of small molecules through the BBB: A technical overview","volume":"41","author":"Chowdhury","year":"2021","journal-title":"Journal of Cerebral Blood Flow & Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0210","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","article-title":"Novel tau fragments in cerebrospinal fluid: Relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease","volume":"137","author":"Cicognola","year":"2019","journal-title":"Acta Neuropathologica"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109084_bb0215","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","article-title":"Tau-targeting therapies for Alzheimer disease: Current status and future directions","volume":"19","author":"Congdon","year":"2023","journal-title":"Nature Reviews Neurology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb0220","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1007\/s00259-021-05231-4","article-title":"First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET","volume":"48","author":"Coughlin","year":"2021","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb0225","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","article-title":"Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"Acta Neuropathologica"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: Appropriate use recommendations","volume":"10","author":"Cummings","year":"2023","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0235","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s40259-023-00633-2","article-title":"Anti-amyloid monoclonal antibodies for the treatment of Alzheimer\u2019s Disease","volume":"38","author":"Cummings","year":"2024","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb0240","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1039\/C6SC04797A","article-title":"Pyroglutamate-modified a\u03b2(3-42) affects aggregation kinetics of a\u03b2(1-42) by accelerating primary and secondary pathways","volume":"8","author":"Dammers","year":"2017","journal-title":"Chemical Science"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0245","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.3390\/cimb45110553","article-title":"Untangling tau: Molecular insights into neuroinflammation, pathophysiology, and emerging immunotherapies","volume":"45","author":"Davidson","year":"2023","journal-title":"Current Issues in Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0250","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41467-019-09477-3","article-title":"Different soluble aggregates of A\u03b242 can give rise to cellular toxicity through different mechanisms","volume":"10","author":"De","year":"2019","journal-title":"Nature Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0255","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer's Disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0260","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2024.1326784","article-title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","volume":"18","author":"Doran","year":"2024","journal-title":"Frontiers in Neuroscience"},{"issue":"Supplement 2","key":"10.1016\/j.pharmthera.2026.109084_bb0265","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.2967\/jnumed.125.270152","article-title":"Imaging and fluid biomarkers of Alzheimer Disease: Complementation rather than competition","volume":"66","author":"Drzezga","year":"2025","journal-title":"Journal of Nuclear Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109084_bb0270","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00259-023-06331-z","article-title":"[18F]FNDP PET neuroimaging test\u2013retest repeatability and whole-body dosimetry in humans","volume":"50","author":"Du","year":"2023","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0275","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Recommendations of the international working group","volume":"20","author":"Dubois","year":"2021","journal-title":"The Lancet Neurology"},{"issue":"8\u20139","key":"10.1016\/j.pharmthera.2026.109084_bb0280","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/emmm.200900048","article-title":"Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer\u2019s disease","volume":"1","author":"Fagan","year":"2009","journal-title":"EMBO Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0285","author":"FDA"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0290","author":"FDA"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0295","author":"FDA"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0300","author":"FDA"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0305","author":"FDA"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2025.1658776","article-title":"A multi-view multimodal deep learning framework for Alzheimer's disease diagnosis","volume":"19","author":"Feng","year":"2025","journal-title":"Frontiers in Neuroscience"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0315","article-title":"Curcumin and cognitive function: A systematic review of the effects of curcumin on adults with and without neurocognitive disorders","volume":"16","author":"Francis","year":"2024","journal-title":"Cureus"},{"issue":"10510","key":"10.1016\/j.pharmthera.2026.109084_bb0320","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(25)01294-2","article-title":"New landscape of the diagnosis of Alzheimer\u2019s disease","volume":"406","author":"Frisoni","year":"2025","journal-title":"The Lancet"},{"issue":"50","key":"10.1016\/j.pharmthera.2026.109084_bb0325","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1021\/bi500910b","article-title":"Capping of A\u03b242 oligomers by small molecule inhibitors","volume":"53","author":"Fu","year":"2014","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0330","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1248\/bpb.b22-00797","article-title":"Plantainoside B in Bacopa monniera binds to a\u03b2 aggregates attenuating neuronal damage and memory deficits induced by a\u03b2","volume":"46","author":"Fukuda","year":"2023","journal-title":"Biological and Pharmaceutical Bulletin"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bib1321","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/brain\/awaa098","article-title":"Neurofilaments: Neurobiological foundations for biomarker applications","volume":"143","author":"Gafson","year":"2020","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0335","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1007\/s12032-025-03061-0","article-title":"Theranostics in nuclear medicine: The era of precision oncology","volume":"42","author":"Gandhi","year":"2025","journal-title":"Medical Oncology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0340","doi-asserted-by":"crossref","first-page":"10038","DOI":"10.1021\/acsomega.5c10926","article-title":"Photophysical and photochemical properties of a curcumins family: A combined computational and experimental investigation","volume":"11","author":"Ghiami-Shomami","year":"2026","journal-title":"ACS Omega"},{"issue":"573","key":"10.1016\/j.pharmthera.2026.109084_bb0345","doi-asserted-by":"crossref","first-page":"eabb1206","DOI":"10.1126\/scitranslmed.abb1206","article-title":"An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer\u2019s disease","volume":"12","author":"Ghosh","year":"2020","journal-title":"Science Translational Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0350","doi-asserted-by":"crossref","first-page":"8192","DOI":"10.1002\/alz.14223","article-title":"Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab","volume":"20","author":"Gibson","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb0355","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.7150\/thno.130380","article-title":"Carbon dots penetrating the blood-brain barrier for central nervous system nanomedicine","volume":"16","author":"Girma","year":"2026","journal-title":"Theranostics"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb0360","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1038\/s41591-023-02543-w","article-title":"Senolytic therapy in mild Alzheimer\u2019s disease: A phase 1 feasibility trial","volume":"29","author":"Gonzales","year":"2023","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40478-018-0508-2","article-title":"Rapid and ultra-sensitive quantitation of disease-associated \u03b1-synuclein seeds in brain and cerebrospinal fluid by \u03b1Syn RT-QuIC","volume":"6","author":"Groveman","year":"2018","journal-title":"Acta Neuropathologica Communications"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0370","first-page":"218","article-title":"Epigallocatechin 3-gallate as an inhibitor of tau phosphorylation and aggregation: A molecular and structural insight","volume":"4","author":"Gu\u00e9roux","year":"2017","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109084_bb0375","doi-asserted-by":"crossref","first-page":"15317","DOI":"10.1074\/jbc.M110.209296","article-title":"Seeding of Normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles","volume":"286","author":"Guo","year":"2011","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0380","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","article-title":"Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer\u2019s mouse phenotypes","volume":"20","author":"Haas","year":"2017","journal-title":"Cell Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0385","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer\u2019s amyloid \u03b2-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"49","key":"10.1016\/j.pharmthera.2026.109084_bb0390","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2210766119","article-title":"Early diagnosis and treatment of Alzheimer\u2019s disease by targeting toxic soluble a\u03b2 oligomers","volume":"119","author":"Habashi","year":"2022","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0395","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer\u2019s disease","volume":"2","author":"Hampel","year":"2022","journal-title":"Nature Aging"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb0400","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nature Reviews Neurology"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb0405","doi-asserted-by":"crossref","first-page":"5481","DOI":"10.1038\/s41380-021-01249-0","article-title":"The amyloid-\u03b2 pathway in Alzheimer\u2019s Disease","volume":"26","author":"Hampel","year":"2021","journal-title":"Molecular Psychiatry"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109084_bb0410","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1016\/j.neuron.2023.05.017","article-title":"Blood-based biomarkers for Alzheimer\u2019s disease: Current state and future use in a transformed global healthcare landscape","volume":"111","author":"Hampel","year":"2023","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0415","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.celrep.2019.12.030","article-title":"GluN2A NMDA receptor enhancement improves brain oscillations, synchrony, and cognitive functions in Dravet syndrome and Alzheimer\u2019s Disease models","volume":"30","author":"Hanson","year":"2020","journal-title":"Cell Reports"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb0420","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0425","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12916-025-04169-w","article-title":"Trend analysis and future predictions of global burden of alzheimer's disease and other dementias: A study based on the global burden of disease database from 1990 to 2021","volume":"23","author":"Hao","year":"2025","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0430","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1038\/s41598-019-45168-1","article-title":"Rosmarinic acid suppresses Alzheimer's disease development by reducing amyloid \u03b2 aggregation by increasing monoamine secretion","volume":"9","author":"Hase","year":"2019","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.620","article-title":"Hippocampal atrophy and memory dysfunction associated with physical inactivity in community-dwelling elderly subjects: The Sefuri study","volume":"7","author":"Hashimoto","year":"2017","journal-title":"Brain and Behavior"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb0440","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","article-title":"Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain","volume":"32","author":"Hey","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0445","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40478-015-0204-4","article-title":"Preventive methylene blue treatment preserves cognition in mice expressing full-length pro-aggregant human tau","volume":"3","author":"Hochgr\u00e4fe","year":"2015","journal-title":"Acta Neuropathologica Communications"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0450","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/brain\/awaa373","article-title":"CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer\u2019s disease","volume":"144","author":"Horie","year":"2021","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0455","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease","volume":"31","author":"Horie","year":"2025","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0460","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2967\/jnumed.116.173245","article-title":"18 F-FNDP for PET imaging of soluble epoxide hydrolase","volume":"57","author":"Horti","year":"2016","journal-title":"Journal of Nuclear Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0465","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1038\/s41467-023-41241-6","article-title":"Methylene blue accelerates liquid-to-gel transition of tau condensates impacting tau function and pathology","volume":"14","author":"Huang","year":"2023","journal-title":"Nature Communications"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109084_bb0470","doi-asserted-by":"crossref","first-page":"6471","DOI":"10.1016\/j.bmc.2014.09.032","article-title":"Phosphorylation regulates fibrillation of an aggregation core peptide in the second repeat of microtubule-binding domain of human tau","volume":"22","author":"Inoue","year":"2014","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0475","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1007\/s11010-025-05211-4","article-title":"Epigallocatechin 3-gallate-induced neuroprotection in neurodegenerative diseases: Molecular mechanisms and clinical insights","volume":"480","author":"Islam","year":"2025","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0480","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0485","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0490","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: An updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0495","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1474-4422(09)70299-6","article-title":"Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade","volume":"9","author":"Jack","year":"2010","journal-title":"The Lancet Neurology"},{"issue":"45","key":"10.1016\/j.pharmthera.2026.109084_bb0500","doi-asserted-by":"crossref","first-page":"21031","DOI":"10.1039\/D1NJ04453B","article-title":"Destabilization of Alzheimer\u2019s A\u03b242 protofibrils with acyclovir, carmustine, curcumin, and tetracycline: Insights from molecular dynamics simulations","volume":"45","author":"Jahan","year":"2021","journal-title":"New Journal of Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0505","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","article-title":"Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease","volume":"11","author":"Janelidze","year":"2020","journal-title":"Nature Communications"},{"issue":"S5","key":"10.1016\/j.pharmthera.2026.109084_bb0510","doi-asserted-by":"crossref","DOI":"10.1002\/alz70859_103102","article-title":"PRImus-AD study: Design of the phase 2 study treating patients with MCI or mild dementia due to Alzheimer's disease (AD) with the orally available PRI-002","volume":"21","author":"J\u00fcrgens","year":"2025","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0515","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/s41467-024-46876-7","article-title":"Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology","volume":"15","author":"Kac","year":"2024","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0520","series-title":"Neuroprotective Insights into Epigallocatechin Gallate (EGCG) for Neurodegenerative Disorders","first-page":"100673","volume":"4","author":"Kamboj","year":"2025"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb0525","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: A diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0530","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1038\/s41467-024-47971-5","article-title":"Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases","volume":"15","author":"Karlsson","year":"2024","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb0535","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2022.100630","article-title":"A\u03b2 oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo","volume":"3","author":"Kass","year":"2022","journal-title":"Cell Reports Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb0540","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1093\/brain\/awad159","article-title":"The amyloid cascade hypothesis: An updated critical review","volume":"146","author":"Kepp","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0545","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ijbiomac.2018.12.271","article-title":"Molecular docking of A\u03b21\u201340 peptide and its Iowa D23N mutant using small molecule inhibitors: Possible mechanisms of a\u03b2-peptide inhibition","volume":"127","author":"Khan","year":"2019","journal-title":"International Journal of Biological Macromolecules"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb0550","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: From discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"Journal of Internal Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0555","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/ana.20009","article-title":"Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh compound-B","volume":"55","author":"Klunk","year":"2004","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","article-title":"The centiloid project: Standardizing quantitative amyloid plaque estimation by PET","volume":"11","author":"Klunk","year":"2015","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0565","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40263-017-0434-z","article-title":"Elucidating the A\u03b242 anti-aggregation mechanism of action of Tramiprosate in Alzheimer\u2019s disease: Integrating molecular analytical methods, pharmacokinetic and clinical data","volume":"31","author":"Kocis","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0570","doi-asserted-by":"crossref","DOI":"10.1038\/srep43155","article-title":"Integrated organotypic slice cultures and RT-QuIC (OSCAR) assay: Implications for translational discovery in protein misfolding diseases","volume":"7","author":"Kondru","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0575","doi-asserted-by":"crossref","DOI":"10.3389\/fmedt.2025.1654003","article-title":"Nanoparticles: A new frontier in neurodegenerative disease therapy","volume":"7","author":"Kumar","year":"2025","journal-title":"Frontiers in Medical Technology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0580","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1038\/s41467-025-59295-z","article-title":"Oral PRI-002 treatment in patients with MCI or mild AD: A randomized, double-blind phase 1b trial","volume":"16","author":"Kutzsche","year":"2025","journal-title":"Nature Communications"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18443","article-title":"Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs \u2013 A model of sporadic Alzheimer\u2019s disease","volume":"9","author":"Kutzsche","year":"2023","journal-title":"Heliyon"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0590","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from A\u03b21\u201342 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00321","article-title":"Disentangling tau: One protein, many therapeutic approaches","volume":"21","author":"Lane-Donovan","year":"2024","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0600","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: Where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nature Reviews Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0605","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14528","article-title":"Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease","volume":"21","author":"Leuzy","year":"2025","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109084_bb0610","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012727","article-title":"Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 assays","volume":"97","author":"Leuzy","year":"2021","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb0615","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1002\/alz.13908","article-title":"Harmonizing tau positron emission tomography in Alzheimer\u2019s disease: The CenTauR scale and the joint propagation model","volume":"20","author":"Leuzy","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0620","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-\u03b2 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer\u2019s Disease: Validation of two novel assays","volume":"43","author":"Lewczuk","year":"2014","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0625","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-160722","article-title":"Cerebrospinal fluid A\u03b242\/40 corresponds better than A\u03b242 to amyloid PET in Alzheimer\u2019s Disease","volume":"55","author":"Lewczuk","year":"2016","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0350-4","article-title":"A pharmacological chaperone improves memory by reducing a\u03b2 and tau neuropathology in a mouse model with plaques and tangles","volume":"15","author":"Li","year":"2020","journal-title":"Molecular Neurodegeneration"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuroimage.2024.120825","article-title":"Brain age prediction via cross-stratified ensemble learning","volume":"299","author":"Li","year":"2024","journal-title":"Neuroimage"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb0640","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1002\/jcp.30864","article-title":"Endosomal trafficking and related genetic underpinnings as a hub in Alzheimer's disease","volume":"237","author":"Limone","year":"2022","journal-title":"Journal of Cellular Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0645","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1038\/s41467-024-49258-1","article-title":"Ligand-based design of [18F]OXD-2314 for PET imaging in non-Alzheimer\u2019s disease tauopathies","volume":"15","author":"Lindberg","year":"2024","journal-title":"Nature Communications"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109084_bb0650","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41594-020-0505-6","article-title":"Kinetic fingerprints differentiate the mechanisms of action of anti-a\u03b2 antibodies","volume":"27","author":"Linse","year":"2020","journal-title":"Nature Structural & Molecular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0655","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13195-024-01599-1","article-title":"Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer's disease","volume":"16","author":"Long","year":"2024","journal-title":"Alzheimer's Research & Therapy"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb0660","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1038\/s41591-023-02541-y","article-title":"Senolytic therapy for Alzheimer\u2019s disease","volume":"29","author":"Longo","year":"2023","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0665","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2967\/jnmt.123.265502","article-title":"Neurotheranostics: The next frontier for health span","volume":"51","author":"Losee","year":"2023","journal-title":"Journal of Nuclear Medicine Technology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0670","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1074\/jbc.M112.393751","article-title":"Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice","volume":"288","author":"Ma","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0675","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.122.265200","article-title":"The use of tau PET to stage Alzheimer Disease according to the Braak staging framework","volume":"64","author":"Macedo","year":"2023","journal-title":"Journal of Nuclear Medicine"},{"issue":"S21","key":"10.1016\/j.pharmthera.2026.109084_bb0680","doi-asserted-by":"crossref","DOI":"10.1002\/alz.074181","article-title":"PRX005, a novel anti-MTBR tau monoclonal antibody: Results from a first-in-human double-blind, placebo-controlled, single ascending dose phase 1 study","volume":"19","author":"Martenyi","year":"2023","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb0685","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/jamaneurol.2019.0765","article-title":"Association between longitudinal plasma Neurofilament light and neurodegeneration in patients with Alzheimer Disease","volume":"76","author":"Mattsson","year":"2019","journal-title":"JAMA Neurology"},{"issue":"16","key":"10.1016\/j.pharmthera.2026.109084_bb0690","doi-asserted-by":"crossref","first-page":"eaaz2387","DOI":"10.1126\/sciadv.aaz2387","article-title":"A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer\u2019s disease","volume":"6","author":"Mattsson-Carlgren","year":"2020","journal-title":"Science Advances"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0695","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114022","article-title":"Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau","volume":"13","author":"Mattsson-Carlgren","year":"2021","journal-title":"EMBO Molecular Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0700","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb0705","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/alz.12097","article-title":"In vivo measurement of widespread synaptic loss in Alzheimer\u2019s disease with SV2A PET","volume":"16","author":"Mecca","year":"2020","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0710","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13195-020-0582-0","article-title":"PET imaging of mGluR5 in Alzheimer\u2019s disease","volume":"12","author":"Mecca","year":"2020","journal-title":"Alzheimer\u2019s Research & Therapy"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1271203","article-title":"GABAA receptors as plausible molecular targets and mediators for taurine and homotaurine actions","volume":"14","author":"Meera","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109084_bb0720","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2967\/jnumed.118.213140","article-title":"Antibody-based in vivo PET imaging detects amyloid-\u03b2 reduction in Alzheimer transgenic mice after BACE-1 inhibition","volume":"59","author":"Meier","year":"2018","journal-title":"Journal of Nuclear Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0725","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038903","article-title":"Fibril-forming motifs are essential and sufficient for the fibrillization of human tau","volume":"7","author":"Meng","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0730","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/brain\/awac459","article-title":"Blood\u2013brain barrier opening of the default mode network in Alzheimer\u2019s disease with magnetic resonance-guided focused ultrasound","volume":"146","author":"Meng","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0735","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nature Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109084_bb0740","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0745","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0750","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neurobiolaging.2015.11.004","article-title":"Curcumin improves tau-induced neuronal dysfunction of nematodes","volume":"39","author":"Miyasaka","year":"2016","journal-title":"Neurobiology of Aging"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0755","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","article-title":"Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: A longitudinal observational study","volume":"21","author":"Morenas-Rodr\u00edguez","year":"2022","journal-title":"The Lancet Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2024.107163","article-title":"A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein","volume":"300","author":"Mortelecque","year":"2024","journal-title":"Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0765","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jama.2025.7817","article-title":"Frequency and clinical outcomes associated with tau positron emission tomography positivity","volume":"334","author":"Moscoso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0770","first-page":"6708","article-title":"Therapeutic potential of oral ALZ-801 in patients with Alzheimer's disease","author":"Muramatsu","year":"2026","journal-title":"Internal Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0775","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202402622R","article-title":"ALZ-801 prevents amyloid \u03b2-protein assembly and reduces cytotoxicity: A preclinical experimental study","volume":"39","author":"Muramatsu","year":"2025","journal-title":"The FASEB Journal"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0780","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12840","article-title":"Tau protein aggregation is associated with cellular senescence in the brain","volume":"17","author":"Musi","year":"2018","journal-title":"Aging Cell"},{"issue":"7691","key":"10.1016\/j.pharmthera.2026.109084_bb0785","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature25456","article-title":"High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease","volume":"554","author":"Nakamura","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0790","series-title":"Handbook of Aging, Health and Public Policy","article-title":"Global Population Aging, 1950\u20132050","author":"Navaneetham","year":"2023"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109084_bb0795","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jalz.2018.06.1353","article-title":"Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale","volume":"14","author":"Navitsky","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0800","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13024-023-00620-9","article-title":"Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer\u2019s Disease drug candidate","volume":"18","author":"Nemergut","year":"2023","journal-title":"Molecular Neurodegeneration"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0805","doi-asserted-by":"crossref","DOI":"10.3390\/life11010028","article-title":"Tau oligomers neurotoxicity","volume":"11","author":"Niewiadomska","year":"2021","journal-title":"Life"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0810","first-page":"1016","article-title":"Considerations on the advantages of Small tracers for optical molecular imaging","volume":"2","author":"Oliveira","year":"2015","journal-title":"Journal of Molecular Biology and Molecular Imaging"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb0815","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer's disease: A systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"The Lancet Neurology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0820","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jnr.20025","article-title":"Curcumin has potent anti-amyloidogenic effects for Alzheimer's \u03b2-amyloid fibrils in vitro","volume":"75","author":"Ono","year":"2004","journal-title":"Journal of Neuroscience Research"},{"issue":"S7","key":"10.1016\/j.pharmthera.2026.109084_bb0825","doi-asserted-by":"crossref","DOI":"10.1002\/alz70861_108042","article-title":"Nano-space video-imaging reveals action of ADUCANUMAB to amyloid \u03b2 aggregates: The comparison with the action of LECANEMAB","volume":"21","author":"Ono","year":"2025","journal-title":"Alzheimer's & Dementia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0830","doi-asserted-by":"crossref","DOI":"10.1177\/0300060520917270","article-title":"Utility of VSRAD for diagnosing Alzheimer's disease in patients screened for dementia","volume":"48","author":"Oshikubo","year":"2020","journal-title":"The Journal of International Medical Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0835","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/s41593-025-02000-6","article-title":"Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-\u03b2 status, APOE genotype and sex","volume":"28","author":"Ossenkoppele","year":"2025","journal-title":"Nature Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0840","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","article-title":"Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline","volume":"28","author":"Ossenkoppele","year":"2022","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0845","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006875","article-title":"Associations between tau, a\u03b2, and cortical thickness with cognition in Alzheimer disease","volume":"92","author":"Ossenkoppele","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0850","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/jmri.70118","article-title":"Unchanged early diffusion tensor imaging along perivascular space index after amyloid-targeting Disease-modifying therapy in Alzheimer's Disease: A preliminary study","volume":"62","author":"Oura","year":"2025","journal-title":"Journal of Magnetic Resonance Imaging"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0855","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.619667","article-title":"Natural compounds as inhibitors of a\u03b2 peptide aggregation: Chemical requirements and molecular mechanisms","volume":"14","author":"Pagano","year":"2020","journal-title":"Frontiers in Neuroscience"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb0860","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma Phospho-tau217 for Alzheimer Disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0865","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/brain\/aww015","article-title":"Cerebrospinal fluid analysis detects cerebral amyloid-\u03b2 accumulation earlier than positron emission tomography","volume":"139","author":"Palmqvist","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0870","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1392729","article-title":"Oligomeric amyloid-\u03b2 targeted contrast agent for MRI evaluation of Alzheimer\u2019s disease mouse models","volume":"15","author":"Park","year":"2024","journal-title":"Frontiers in Pharmacology"},{"issue":"46","key":"10.1016\/j.pharmthera.2026.109084_bb0875","doi-asserted-by":"crossref","first-page":"11194","DOI":"10.1039\/C5OB01847A","article-title":"A curcumin-based molecular probe for near-infrared fluorescence imaging of tau fibrils in Alzheimer\u2019s disease","volume":"13","author":"Park","year":"2015","journal-title":"Organic & Biomolecular Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0880","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s44328-024-00023-w","article-title":"A same day \u03b1-synuclein RT-QuIC seed amplification assay for synucleinopathy biospecimens","volume":"2","author":"Parveen","year":"2025","journal-title":"Npj Biosensing"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb0885","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/mabi.201500062","article-title":"Curcumin targeted, polymalic acid-based MRI contrast agent for the detection of a\u03b2 plaques in Alzheimer\u2019s disease: Curcumin targeted, polymalic acid-based MRI contrast","volume":"15","author":"Patil","year":"2015","journal-title":"Macromolecular Bioscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb0890","doi-asserted-by":"crossref","first-page":"975","DOI":"10.14283\/jpad.2024.85","article-title":"Safety, efficacy and clinical applications of focused ultrasound-mediated blood brain barrier opening in Alzheimer\u2019s Disease: A systematic review","volume":"11","author":"Patwardhan","year":"2024","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0895","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/alz.13450","article-title":"Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression","volume":"20","author":"Pelkmans","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0900","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/brain\/awab223","article-title":"Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease","volume":"144","author":"Pereira","year":"2021","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0905","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1039\/D3CB00073G","article-title":"Small molecules and conjugates as theranostic agents","volume":"4","author":"Pratihar","year":"2023","journal-title":"RSC Chemical Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0910","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"Supplement 2","key":"10.1016\/j.pharmthera.2026.109084_bb0915","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2967\/jnumed.124.268756","article-title":"Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer\u2019s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"66","author":"Rabinovici","year":"2025","journal-title":"Journal of Nuclear Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb0920","article-title":"Donanemab: Appropriate use recommendations","volume":"12","author":"Rabinovici","year":"2025","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0925","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40478-025-02096-8","article-title":"Stabilizing the retromer complex rescues synaptic dysfunction and endosomal trafficking deficits in an Alzheimer's disease mouse model","volume":"13","author":"Ramonet","year":"2025","journal-title":"Acta Neuropathologica Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0930","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3233\/JAD-170351","article-title":"Curcumin inhibits tau aggregation and disintegrates preformed tau filaments in vitro","volume":"60","author":"Rane","year":"2017","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0935","doi-asserted-by":"crossref","DOI":"10.1007\/s44345-025-00038-4","article-title":"Molecular insights into curcumin\u2019s anti-Alzheimer\u2019s potential through amyloid-\u03b2 and tau interactions","volume":"2","author":"Reddy","year":"2025","journal-title":"Discover Molecules"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0940","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMoa2308719","article-title":"Ultrasound blood\u2013brain barrier opening and aducanumab in Alzheimer\u2019s disease","volume":"390","author":"Rezai","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb0945","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3171\/2022.9.JNS221565","article-title":"Focused ultrasound\u2013mediated blood-brain barrier opening in Alzheimer\u2019s disease: Long-term safety, imaging, and cognitive outcomes","volume":"139","author":"Rezai","year":"2023","journal-title":"Journal of Neurosurgery"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0950","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nbt.1641","article-title":"Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations","volume":"28","author":"Rissin","year":"2010","journal-title":"Nature Biotechnology"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcn.2024.103950","article-title":"Disease modifying effects of the amyloid-beta protofibril-selective antibody mAb158 in aged Tg2576 transgenic mice","volume":"130","author":"Rizoska","year":"2024","journal-title":"Molecular and Cellular Neuroscience"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109084_bb0960","doi-asserted-by":"crossref","first-page":"4406","DOI":"10.1021\/acschemneuro.1c00454","article-title":"Proliferation of tau 304\u2013380 fragment aggregates through autocatalytic secondary nucleation","volume":"12","author":"Rodriguez Camargo","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb0965","doi-asserted-by":"crossref","first-page":"880","DOI":"10.2967\/jnumed.112.114785","article-title":"Head-to-head comparison of11 C-PiB and18 F-AZD4694 (NAV4694) for \u03b2-amyloid imaging in aging and dementia","volume":"54","author":"Rowe","year":"2013","journal-title":"Journal of Nuclear Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb0970","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.110.076315","article-title":"Brain Amyloid Imaging","volume":"52","author":"Rowe","year":"2011","journal-title":"Journal of Nuclear Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb0975","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71112","article-title":"Classification of tauopathies from human brain homogenates through salt-modulated tau amplification","volume":"22","author":"Santambrogio","year":"2026","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0980","series-title":"Tau Kinetics in Neurons and the Human Central Nervous System","author":"Sato","year":"2019"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb0985","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s12035-018-1209-3","article-title":"A\u03b2 oligomer elimination restores cognition in transgenic Alzheimer\u2019s mice with full-blown pathology","volume":"56","author":"Schemmert","year":"2019","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2026.109084_bb0990","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sbi.2020.05.011","article-title":"Cryo-EM structures of tau filaments","volume":"64","author":"Scheres","year":"2020","journal-title":"Current Opinion in Structural Biology"},{"issue":"17","key":"10.1016\/j.pharmthera.2026.109084_bb0995","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler","year":"2019","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb1000","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jalz.2018.01.013","article-title":"Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging","volume":"14","author":"Schindler","year":"2018","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb1005","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Molecular Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb1010","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1021\/jacsau.4c00262","article-title":"Mechanism of methylene blue inducing the disulfide bond formation of tubulin-associated unit proteins","volume":"4","author":"Seo","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1015","article-title":"Investigating the hidden mechanism underlying the tau interaction by methylene blue","author":"Seo","year":"2023","journal-title":"Research Square"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb1020","doi-asserted-by":"crossref","DOI":"10.1002\/nbm.70262","article-title":"Multimodal MRI reveals cerebral and vascular amyloid-driven myeloarchitectural disorganization in a mouse model of Alzheimer\u2019s disease","volume":"39","author":"Shahid","year":"2026","journal-title":"NMR in Biomedicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s12974-021-02340-7","article-title":"Identification of the minimal active soluble TREM2 sequence for modulating microglial phenotypes and amyloid pathology","volume":"18","author":"Sheng","year":"2021","journal-title":"Journal of Neuroinflammation"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109084_bb1030","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.3987\/COM-16-13533","article-title":"Structure-activity relationship of Phenylethanoid glycosides on the inhibition of amyloid \u03b2 aggregation","volume":"92","author":"Shigemori","year":"2016","journal-title":"Heterocycles"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb1035","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.903119","article-title":"Curcumin as a holistic treatment for tau pathology","volume":"13","author":"Sivanantharajah","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb1045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jagp.2017.10.010","article-title":"Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial","volume":"26","author":"Small","year":"2018","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109084_bb1050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.tins.2017.08.003","article-title":"Endosomal traffic jams represent a pathogenic hub and therapeutic target in Alzheimer\u2019s Disease","volume":"40","author":"Small","year":"2017","journal-title":"Trends in Neurosciences"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109084_bb1055","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1021\/acs.jpcb.6b07045","article-title":"Primary fibril nucleation of aggregation prone tau fragments PHF6 and PHF6 *","volume":"121","author":"Smit","year":"2017","journal-title":"The Journal of Physical Chemistry B"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab\u2014Binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer's Disease","volume":"20","author":"S\u00f6derberg","year":"2023","journal-title":"Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb1065","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3233\/JAD-181001","article-title":"Methylene blue inhibits formation of tau fibrils but not of granular tau oligomers: A plausible key to understanding failure of a clinical trial for Alzheimer's Disease","volume":"68","author":"Soeda","year":"2019","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1070","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2023.1314077","article-title":"Introduction to small molecule drug discovery and preclinical development","volume":"3","author":"Southey","year":"2023","journal-title":"Frontiers in Drug Discovery"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/JAD-150167","article-title":"Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer\u2019s Disease","volume":"49","author":"Spiegel","year":"2015","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"647","key":"10.1016\/j.pharmthera.2026.109084_bb1080","doi-asserted-by":"crossref","first-page":"eabi8593","DOI":"10.1126\/scitranslmed.abi8593","article-title":"Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q","volume":"14","author":"Spurrier","year":"2022","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1085","doi-asserted-by":"crossref","first-page":"33840","DOI":"10.1038\/s41598-025-04899-0","article-title":"Advanced MRI based Alzheimer\u2019s diagnosis through ensemble learning techniques","volume":"15","author":"Sriram","year":"2025","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00441-022-03595-z","article-title":"Seed amplification and RT-QuIC assays to investigate protein seed structures and strains","volume":"392","author":"Standke","year":"2023","journal-title":"Cell and Tissue Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb1095","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jalz.2018.07.219","article-title":"Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance","volume":"16","author":"Stern","year":"2020","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1100","doi-asserted-by":"crossref","DOI":"10.1038\/srep35636","article-title":"Fluselenamyl: A novel Benzoselenazole derivative for PET detection of amyloid plaques (a\u03b2) in Alzheimer\u2019s Disease","volume":"6","author":"Sundaram","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuron.2020.09.042","article-title":"High-contrast in vivo imaging of tau pathologies in Alzheimer's and non-Alzheimer's Disease Tauopathies","volume":"109","author":"Tagai","year":"2021","journal-title":"Neuron"},{"issue":"S21","key":"10.1016\/j.pharmthera.2026.109084_bb1110","article-title":"APNmAb005, an anti-tau antibody targeting synaptic tau oligomers, in phase 1 for treatment of Alzheimer\u2019s disease and primary tauopathies","volume":"19","author":"Tai","year":"2023","journal-title":"Alzheimer\u2019s & Dementia\u202f: The Journal of the Alzheimer\u2019s Association"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1115","article-title":"The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatments","author":"Tai","year":"2022","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109084_bb1120","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1021\/acsmedchemlett.2c00138","article-title":"Identification of \u03b1-Synuclein Proaggregator: Rapid synthesis and streamlining RT-QuIC assays in Parkinson's Disease","volume":"13","author":"Takada","year":"2022","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb1125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27052370","article-title":"From polyphenols to prodrugs: Bridging the blood\u2013brain barrier with nanomedicine and neurotherapeutics","volume":"27","author":"Tanaka","year":"2026","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1130","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/19336896.2020.1832946","article-title":"RT-QuIC detection of tauopathies using full-length tau substrates","volume":"14","author":"Tennant","year":"2020","journal-title":"Prion"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109084_bb1135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220664120","article-title":"Direct observation of secondary nucleation along the fibril surface of the amyloid \u03b2 42 peptide","volume":"120","author":"Thacker","year":"2023","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb1140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","article-title":"Biomarker-based staging of Alzheimer disease: Rationale and clinical applications","volume":"20","author":"Therriault","year":"2024","journal-title":"Nature Reviews Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb1145","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","article-title":"Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography","volume":"80","author":"Therriault","year":"2023","journal-title":"JAMA Neurology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb1150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109084_bb1155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1267\/ahc.23-00058","article-title":"Visualization of amyloid oligomers in the brain of patients with Alzheimer's Disease","volume":"56","author":"Tooyama","year":"2023","journal-title":"Acta Histochemica et Cytochemica"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1326-9-48","article-title":"Oligomeric a\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease","volume":"9","author":"Tu","year":"2014","journal-title":"Molecular Neurodegeneration"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109084_bb1165","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3233\/JAD-140741","article-title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 Protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","volume":"43","author":"Tucker","year":"2015","journal-title":"Journal of Alzheimer\u2019s Disease"},{"issue":"S8","key":"10.1016\/j.pharmthera.2026.109084_bb1170","doi-asserted-by":"crossref","DOI":"10.1002\/alz.094677","article-title":"TargetTau-1: Design of a phase 2 trial to evaluate the efficacy, safety, and tolerability of BMS-986446, an anti-MTBR tau monoclonal antibody, in patients with early Alzheimer\u2019s disease","volume":"20","author":"Van Dyck","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb1175","doi-asserted-by":"crossref","first-page":"494","DOI":"10.2967\/jnumed.125.271895","article-title":"Theranostics explained: A personalized approach to Cancer care","volume":"67","author":"Viana","year":"2026","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100631","article-title":"Wild-type sTREM2 blocks a\u03b2 aggregation and neurotoxicity, but the Alzheimer\u2019s R47H mutant increases a\u03b2 aggregation","volume":"296","author":"Vilalta","year":"2021","journal-title":"Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb1185","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","article-title":"Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer\u2019s disease: A prospective cohort study","volume":"12","author":"Villemagne","year":"2013","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1190","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15701-2","article-title":"Spread of pathological tau proteins through communicating neurons in human Alzheimer\u2019s disease","volume":"11","author":"Vogel","year":"2020","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb1195","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A\u03b2 oligomers \u2013 A decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13195-024-01385-z","article-title":"Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer's disease: A [18F]PSS232 PET\/MRI study","volume":"16","author":"Wang","year":"2024","journal-title":"Alzheimer's Research & Therapy"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1205","article-title":"Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis","volume":"16","author":"Wang","year":"2024","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1210","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13024-025-00844-x","article-title":"Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model","volume":"20","author":"Wang","year":"2025","journal-title":"Molecular Neurodegeneration"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb1215","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1042\/BST20120134","article-title":"Tau oligomers and tau toxicity in neurodegenerative disease","volume":"40","author":"Ward","year":"2012","journal-title":"Biochemical Society Transactions"},{"issue":"13","key":"10.1016\/j.pharmthera.2026.109084_bb1220","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.1021\/acs.nanolett.3c00187","article-title":"Structural dynamics of amyloid-\u03b2 Protofibrils and actions of anti-amyloid-\u03b2 antibodies as observed by high-speed atomic force microscopy","volume":"23","author":"Watanabe-Nakayama","year":"2023","journal-title":"Nano Letters"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109084_bb1225","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/cbic.200300631","article-title":"Selection of D -amino-acid peptides that bind to Alzheimer\u2019s Disease amyloid peptide A\u03b21\u201342 by mirror image phage display","volume":"4","author":"Wiesehan","year":"2003","journal-title":"ChemBioChem"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109084_bb1230","doi-asserted-by":"crossref","first-page":"780","DOI":"10.14283\/jpad.2022.63","article-title":"Oral tau aggregation inhibitor for Alzheimer\u2019s Disease: Design, progress and basis for selection of the 16 mg\/day dose in a phase 3, randomized, placebo-controlled trial of hydromethylthionine mesylate","volume":"9","author":"Wischik","year":"2022","journal-title":"The Journal of Prevention of Alzheimer\u2019s Disease"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb1240","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1523\/JNEUROSCI.2381-04.2005","article-title":"Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death","volume":"25","author":"Wogulis","year":"2005","journal-title":"The Journal of Neuroscience"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb1245","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1021\/acs.jmedchem.4c00179","article-title":"Novel PET imaging probe for quantitative detection of senescence in vivo","volume":"67","author":"Xiang","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1250","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.789054","article-title":"18F-APN-1607 tau positron emission tomography imaging for evaluating disease progression in Alzheimer's Disease","volume":"13","author":"Xu","year":"2022","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109084_bb1255","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120686","article-title":"Keto form of curcumin derivatives strongly binds to a\u03b2 oligomers but not fibrils","volume":"270","author":"Yanagisawa","year":"2021","journal-title":"Biomaterials"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109084_bb1260","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb1265","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/acschemneuro.4c00532","article-title":"Novel dual-functional half-curcumin analogues as a fluorescent and PET probe for \u03b2-amyloid imaging in the Alzheimer's Disease APP\/PS1 model","volume":"16","author":"Yang","year":"2025","journal-title":"ACS Chemical Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109084_bb1270","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.3390\/molecules27123879","article-title":"Curcumin scaffold as a multifunctional tool for Alzheimer's Disease research","volume":"27","author":"Yang","year":"2022","journal-title":"Molecules (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1275","article-title":"Effects of Phenylethanoid glycosides extracted from Herba Cistanches on the learning and memory of the APP\/PSI transgenic mice with Alzheimer's Disease","volume":"2021","author":"Yang","year":"2021","journal-title":"BioMed Research International"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb1280","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.fshw.2021.12.006","article-title":"Multifaceted neuroprotective effects of (\u2212)-epigallocatechin-3-gallate (EGCG) in Alzheimer's disease: An overview of pre-clinical studies focused on \u03b2-amyloid peptide","volume":"11","author":"Youn","year":"2022","journal-title":"Food Science and Human Wellness"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1285","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40035-025-00490-9","article-title":"Immunization targeting diseased proteins in synucleinopathy and tauopathy: Insights from clinical trials","volume":"14","author":"Zhan","year":"2025","journal-title":"Translational Neurodegeneration"},{"issue":"526","key":"10.1016\/j.pharmthera.2026.109084_bb1290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aay6931","article-title":"\u03b2-Amyloid redirects norepinephrine signaling to activate the pathogenic GSK3\u03b2\/tau cascade","volume":"12","author":"Zhang","year":"2020","journal-title":"Science Translational Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1295","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13024-025-00834-z","article-title":"TREM2 and sTREM2 in Alzheimer's disease: From mechanisms to therapies","volume":"20","author":"Zhang","year":"2025","journal-title":"Molecular Neurodegeneration"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb1300","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41593-019-0372-9","article-title":"Senolytic therapy alleviates a\u03b2-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer\u2019s disease model","volume":"22","author":"Zhang","year":"2019","journal-title":"Nature Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109084_bb1305","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1021\/acschemneuro.9b00458","article-title":"Toward the mode of action of the clinical stage all- D -enantiomeric peptide RD2 on A\u03b242 aggregation","volume":"10","author":"Zhang","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109084_bb1310","article-title":"Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model","volume":"10","author":"Zhong","year":"2019","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109084_bb1315","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.70802","article-title":"Recent advancements in neuroimaging-based Alzheimer\u2019s disease prediction using deep learning approaches in e-health: A systematic review","volume":"8","author":"Zia-Ur-Rehman","year":"2025","journal-title":"Health Science Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109084_bb1320","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1021\/acschemneuro.8b00537","article-title":"Norepinephrine inhibits Alzheimer's amyloid-\u03b2 peptide aggregation and destabilizes amyloid-\u03b2 Protofibrils: A molecular dynamics simulation study","volume":"10","author":"Zou","year":"2019","journal-title":"ACS Chemical Neuroscience"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:05Z","timestamp":1786119365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":264,"alternative-id":["S0163725826001117"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109084","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109084"}}